First patient in Oncoinvent trial treated for colorectal cancer

By AuntMinnieEurope.com staff writers

August 26, 2022 -- Norwegian radiopharmaceutical developer Oncoinvent is highlighting that the first colorectal cancer patient has been treated in a clinical trial of the company's Radspherin drug candidate.

The RAD-18-002 phase 2A trial is designed to assess the safety, tolerability, and antitumor activity of the drug candidate, an alpha-emitting radionuclide therapy. Radspherin is administered into the intraperitoneal cavity in patients with peritoneal carcinomatosis from colorectal carcinoma following complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC).

Oncoinvent said study goals include survival benefit as well as acute and long-term safety of Radspherin. The study is being conducted at the Radium Hospital in Oslo, Norway, and the Uppsala University Hospital in Uppsala, Sweden. It aims to include a total of 30 patients.


Copyright © 2022 AuntMinnieEurope.com
 

To read this and get access to all of the exclusive content on AuntMinnieEurope.com create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a AuntMinnieEurope.com password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking
account: